Core Viewpoint - Morgan Stanley's report indicates that the inclusion of Eli Lilly's Tirzepatide in the national medical insurance directory was not entirely unexpected, and they believe that Innovent Biologics (01801) can adopt flexible pricing strategies for its Mazdutide product [1] Group 1: Market Potential - The Chinese weight loss drug market is vast, with sufficient space for the development of multiple blockbuster drugs [1] - Morgan Stanley predicts that by 2027, Innovent will have over ten products on the market, with sales potentially reaching 17 billion RMB [1] Group 2: Company Outlook - Innovent Biologics is rated "Overweight" by Morgan Stanley, with a positive outlook on its product pipeline, which includes areas such as oncology, autoimmune diseases, metabolic diseases, and ophthalmology [1] - Investors may focus on the company's ability to license assets externally in the short to medium term [1] Group 3: Stock Performance - On October 8, Innovent's stock price fell by approximately 7%, compared to a 1.5% decline in the Hang Seng Healthcare Index (HSHCI) on the same day [1] - Concerns among investors include the potential impact of Eli Lilly's Tirzepatide on the sales potential of Innovent's Mazdutide, as well as worries about possible excessive price reductions to include small molecule inhibitors in the insurance directory [1]
小摩：料信达生物玛仕度肽可采取灵活定价策略 评级“增持”